- I-ACT for Children Selects Advarra as Central IRB for its Pediatric Clinical Trial Network May 21, 2019 2:11 pm
- Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer May 21, 2019 2:00 pm
- Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research May 21, 2019 2:00 pm
- Columbia Care and Westmed Announce Initiation of a Research Study on the Safety and Efficacy of Precisely Formulated Cannabis-Based Medicines in Rheumatologic Patients May 21, 2019 2:00 pm
- US Breast Cancer Drug Market 2019-2025 Opportunity: $ 20 Billion
- Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline May 21, 2019 12:45 pm
- LineaRx Anticipates Expansion in Diagnostics Market via Follow-on Order and New Linear DNA Amplicons for Additional Assay May 21, 2019 11:30 am
- EXUMA Biotechnology’s Affiliate Shanghai PerHum Therapeutics Announces Preliminary Results of Two First-in-Human Solid Tumor CAR-T Products May 21, 2019 11:00 am
- Debiopharm enrolls patient to test treatment in solid tumors
- Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration May 21, 2019 9:00 am
- First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy May 21, 2019 7:00 am
- Imago BioSciences to Present First Clinical Data for IMG-7289 At 24th Congress of the European Hematology Association May 21, 2019 12:05 am
My Pharmaceutical
Consequences of microbead: What makes microbeads problematic
In the world of great discoveries that cure or add a positive element to our everyday existence, the invention of microbeads hasn’t proven to be one of them. Not alone in its quick rise to popularity and slow journey to extinction, the microbead is just one of numerous products rushed to market before its long term effects are uncovered.
